参考文献/References:
[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.DOI:10.3322/caac.21660.
[2] Cabanillas ME,McFadden DG,Durante C.Thyroid cancer[J].Lancet,2016,388(10061):2783-2795.DOI:10.1016/S0140-6736(16)30172-6.
[3] Kiesewetter B,Riss P,Scheuba C,et al.How I treat medullary thyroid cancer[J].ESMO Open,2021,6(3):100183.DOI:10.1016/j.esmoop.2021.100183.
[4] Molinaro E,Romei C,Biagini A,et al.Anaplastic thyroid carcinoma:from clinicopathology to genetics and advanced therapies[J].Nat Rev Endocrinol,2017,13(11):644-660.DOI:10.1038/nrendo.2017.76.
[5] Durante C,Haddy N,Baudin E,et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab,2006,91(8):2892-2899.DOI:10.1210/jc.2005-2838.
[6] Brose MS,Nutting CM,Jarzab B,et al.Sorafenib in radioactive iodine-refractory,locally advanced or metastatic differentiated thyroid cancer:a randomised,double-blind,phase 3 trial[J].Lancet,2014,384(9940):319-328.DOI:10.1016/S0140-6736(14)60421-9.
[7] Elisei R,Schlumberger MJ,Müller SP,et al.Cabozantinib in progressive medullary thyroid cancer[J].J Clin Oncol,2013,31(29):3639-3646.DOI:10.1200/JCO.2012.48.4659.
[8] Schlumberger M,Tahara M,Wirth LJ,et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].N Engl J Med,2015,372(7):621-630.DOI:10.1056/NEJMoa1406470.
[9] Wells SA,Jr.,Robinson BG,Gagel RF,et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized,double-blind phase Ⅲ trial[J].J Clin Oncol,2012,30(2):134-141.DOI:10.1200/JCO.2011.35.5040.
[10] Subbiah V,Kreitman RJ,Wainberg ZA,et al.Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant anaplastic thyroid cancer[J].J Clin Oncol,2018,36(1):7-13.DOI:10.1200/JCO.2017.73.6785.
[11] Ferris RL.Immunology and immunotherapy of head and neck cancer[J].J Clin Oncol,2015,33(29):3293-3304.DOI:10.1200/JCO.2015.61.1509.
[12] French JD.Immunotherapy for advanced thyroid cancers - rationale,current advances and future strategies[J].Nat Rev Endocrinol,2020,16(11):629-641.DOI:10.1038/s41574-020-0398-9.
[13] Naoum GE,Morkos M,Kim B,et al.Novel targeted therapies and immunotherapy for advanced thyroid cancers[J].Mol Cancer,2018,17(1):51.DOI:10.1186/s12943-018-0786-0.
[14] Daud AI,Loo K,Pauli ML,et al.Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma[J].J Clin Invest,2016,126(9):3447-3452.DOI:10.1172/JCI87324.
[15] Tumeh PC,Harview CL,Yearley JH,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature,2014,515(7528):568-571.DOI:10.1038/nature13954.
[16] Na KJ,Choi H.Immune landscape of papillary thyroid cancer and immunotherapeutic implications[J].Endocr Relat Cancer,2018,25(5):523-531.DOI:10.1530/ERC-17-0532.
[17] Giannini R,Moretti S,Ugolini C,et al.Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes:An ATC-Like and a PDTC-Like[J].J Clin Endocrinol Metab,2019,104(8):3557-3575.DOI:10.1210/jc.2018-01167.
[18] Bongiovanni M,Rebecchini C,Saglietti C,et al.Very low expression of PD-L1 in medullary thyroid carcinoma[J].Endocr Relat Cancer,2017,24(6):L35-L38.DOI:10.1530/ERC-17-0104.
[19] Pozdeyev N,Erickson TA,Zhang L,et al.Comprehensive immune profiling of medullary thyroid cancer.thyroid[J].Thyroid,2020,30(9):1263-1279.DOI:10.1089/thy.2019.0604.
[20] Mehnert JM,Varga A,Brose MS,et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced,PD-L1-positive papillary or follicular thyroid cancer[J].BMC Cancer,2019,19(1):196.DOI:10.1186/s12885-019-5380-3.
[21] Kollipara R,Schneider B,Radovich M,et al.Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[J].Oncologist,2017,22(10):1149-1151.DOI:10.1634/theoncologist.2017-0096.
[22] Spalart V,Legius B,Segers K,et al.Dramatic response to first line single agent pembrolizumab in anaplastic thyroid carcinoma.[J].Case Rep Endocrinol,2019,2019:9095753.DOI:10.1155/2019/9095753.
[23] Capdevila J,Wirth LJ,Ernst T,et al.PD-1 blockade in anaplastic thyroid carcinoma[J].J Clin Oncol,2020,38(23):2620-2627.DOI:10.1200/JCO.19.02727.
[24] Gunda V,Gigliotti B,Ashry T,et al.Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer[J].Int J Cancer,2019,144(9):2266-2278.DOI:10.1002/ijc.32041.
[25] Gunda V,Gigliotti B,Ndishabandi D,et al.Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J].Br J Cancer,2018,119(10):1223-1232.DOI:10.1038/s41416-018-0296-2.
[26] Iyer PC,Dadu R,Gule-Monroe M,et al.Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J].J Immunother Cancer,2018,6(1):68.DOI:10.1186/s40425-018-0378-y.
[27] Gonzalez-Rodriguez E,Rodriguez-Abreu D,Spanish Group for Cancer Immuno-Biotherapy(GETICA).Immune checkpoint inhibitors:review and management of endocrine adverse events[J].Oncologist,2016,21(7):804-816.DOI:10.1634/theoncologist.2015-0509.
相似文献/References:
[1]于亚静 杨彩哲 关小宏 王良宸 吴石白 刘明 肖黎 张妲 刘朝阳.甲状腺癌与桥本甲状腺炎及其他相关危险因素的研究[J].国际内分泌代谢杂志,2015,(01):27.[doi:10.3760/cma.j.issn.1673-4157.2015.01.006]
Yu Yajing*,Yang Caizhe,Guan Xiaohong,et al.Relationship between thyroid carcinoma, Hashimoto′s thyroiditis and other related risk factors[J].International Journal of Endocrinology and Metabolism,2015,(05):27.[doi:10.3760/cma.j.issn.1673-4157.2015.01.006]
[2]李兴佳 曹萌 刘超.自噬与甲状腺癌的关系[J].国际内分泌代谢杂志,2015,(01):56.[doi:10.3760/cma.j.issn.1673-4157.2015.01.014]
Li Xingjia,Cao Meng,Liu Chao..Relationship between autophagy and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2015,(05):56.[doi:10.3760/cma.j.issn.1673-4157.2015.01.014]
[3]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(05):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[4]孟祥慧,徐书杭,蔡可英,等.肥胖与甲状腺癌：临床新启示[J].国际内分泌代谢杂志,2014,(02):87.[doi:10.3760/cma.j.issn.1673-4157.2014.02.005]
Meng Xianghui*,Xu Shuhang,Cai Keying,et al.Obesity and thyroid cancer: a new clinical implication[J].International Journal of Endocrinology and Metabolism,2014,(05):87.[doi:10.3760/cma.j.issn.1673-4157.2014.02.005]
[5]孙洪平,陈国芳,曹雯,等.糖尿病与甲状腺癌关系的研究进展[J].国际内分泌代谢杂志,2014,(02):90.[doi:10.3760/cma.j.issn.1673-4157.2014.02.006]
Sun Hongping,Chen Guofang,Cao Wen,et al.Diabetes and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2014,(05):90.[doi:10.3760/cma.j.issn.1673-4157.2014.02.006]
[6]于亚静,杨彩哲,关小宏,等.桥本甲状腺炎和甲状腺癌的关系[J].国际内分泌代谢杂志,2014,(03):200.[doi:10.3760/cma.j.issn.1673-4157.2014.03.016]
Yu Yajing,Yang Caizhe,Guan Xiaohong,et al.Relationship between Hashimoto's thyroiditis and thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2014,(05):200.[doi:10.3760/cma.j.issn.1673-4157.2014.03.016]
[7]蔡芸莹 苏恒.1型糖尿病的非胰岛素治疗[J].国际内分泌代谢杂志,2015,(06):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
Cai Yunying,Su Heng.Noninsulin management in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
[8]张倍宁 闫如意 周金莲 崔彦.甲状腺癌中miRNA的表达及作用[J].国际内分泌代谢杂志,2018,38(03):167.[doi:10.3760/cma.j.issn.1673-4157.2018.03.006]
Zhang Beining*,Yan Ruyi,Zhou Jinlian,et al.Expression and function of miRNA in thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2018,38(05):167.[doi:10.3760/cma.j.issn.1673-4157.2018.03.006]
[9]任秀利 柳艳萍 宋富军 王亭 倪明 张平平 刘明法.1990—2015年天津市滨海新区甲状腺癌
流行特征及长期发病趋势分析[J].国际内分泌代谢杂志,2020,40(02):73.[doi:10.3760/cma.j.issn.1673-4157.2020.02.001]
Ren Xiuli,Liu Yanping,Song Fujun,et al.Epidemiological characteristics and long-term trends of thyroid cancer in Binhai New Area of Tianjin from 1990 to 2015[J].International Journal of Endocrinology and Metabolism,2020,40(05):73.[doi:10.3760/cma.j.issn.1673-4157.2020.02.001]
[10]陈双,杨涛,顾愹.1型糖尿病的诊断与免疫治疗[J].国际内分泌代谢杂志,2021,41(06):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
Chen Shuang,Yang Tao,Gu Yong..Diagnosis and immunotherapy of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(05):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
[11]何茹,徐加杰.甲状腺癌免疫微环境的研究进展[J].国际内分泌代谢杂志,2023,43(01):30.[doi:10.3760/cma.j.cn121383-20211116-11047]
He Ru,Xu Jiajie..Advances in the study of immune microenvironment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2023,43(05):30.[doi:10.3760/cma.j.cn121383-20211116-11047]